Viking Therapeutics, Inc. - Common Stock (VKTX)

Healthcare stocks provide a combination of upstarts with a high risk, high reward proposition to established firms that can be a defensive maneuver.

The "rapid" enrollment suggests there's still huge interest in the company's approach to obesity treatment.

Stocks gained after the Fed meeting but drifted lower after disappointing guidance from FedEx; next week's inflation data is unlikely to provide needed clarity

Viking Therapeutic may have a GLP-1 blockbuster on their hands with VK2735 as it produces weight loss at 5X the speed of Novo Nordisk's Wegovy GLP-1 drug.

Ignore the noise in GLP-1 stocks. Find the best value instead.

The company will pay CordenPharma $150 million over three years in a manufacturing deal.

This is the drugmaker's first foray into weight-loss drugs. And it's not focusing on GLP-1.

Stocks tried to stage a weak rally to close the week but the short-term outlook will continue to be dictated by the uncertainty that is creating volatility

Viking Therapeutics stock jumped on rumors of a potential acquirer looking to add a GLP-1 treatment to their portfolio and VK2735 appears to rival Zepbound.